|
<!-- Legal status -->|legal_AU=S4|legal_CA=Rx-only|legal_UK=POM|legal_US=Rx-only
<!-- Pharmacokinetic data -->|bioavailability=60-65%<ref>{{cite journal| last1 = Kassahun| first1 = Kelem| last2 = Mattiuz| first2 = Edward| last3 = Nyhart| first3 = Eldon| title = DISPOSITION AND BIOTRANSFORMATION OF THE ANTIPSYCHOTIC AGENT OLANZAPINE IN HUMANS| issue = 1| pages = 81–93| journal = Drug Metabolism and Disposition| volume = 25| date = January 1, 1997| url = http://dmd.aspetjournals.org/content/25/1/81.long| doi = | pmid = 9010634| id = | access-date = February 22, 2019| archive-date = February 22, 2019| archive-url = https://web.archive.org/web/20190222151933/http://dmd.aspetjournals.org/content/25/1/81.long| url-status = live}}</ref><ref>{{cite journal | vauthors= Callaghan JT, Bergstrom RF, Ptak LR, et al| title = Olanzapine: pharmacokinetic and pharmacodynamic profile. | journal = Clin Pharmacokinetics| volume = 37 | issue = 3 | pages = 177–193 | date = September 1999 | pmid = 10511917| doi = 10.2165/00003088-199937030-00001 }}</ref><ref>{{cite journal | vauthors = Mauri MC, Volonteri LS, Colasanti A, et al| s2cid = 43859718 | title = Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. | journal = Clinical Pharmacokinetics | volume = 46 | issue = 5 | pages = 359–88 | date = 2007 | pmid = 17465637| doi = 10.2165/00003088-200746050-00001 }}</ref>|protein_bound=93%<ref name = TGA>{{cite web|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS|work=TGA eBusiness Services|publisher=Sandoz Pty Ltd|date=8 June 2012|accessdate=26 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|format=PDF|archive-date=17 October 2015|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|url-status=live}}</ref>|metabolism=Liver (direct glucuronidation and [[CYP1A2]] mediated oxidation)|elimination_half-life=33 hours, 51.8 hours (elderly)<ref name = TGA>{{cite web|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS|work=TGA eBusiness Services|publisher=Sandoz Pty Ltd|date=8 June 2012|accessdate=26 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|format=PDF|archive-date=17 October 2015|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|url-status=live}}</ref>|excretion=Urine (57%; 7% as unchanged drug), faeces (30%)<ref name = TGA>{{cite web|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS|work=TGA eBusiness Services|publisher=Sandoz Pty Ltd|date=8 June 2012|accessdate=26 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|format=PDF|archive-date=17 October 2015|archive-url=https://web.archive.org/web/20151017030253/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|url-status=live}}</ref><ref name = MSR>{{cite web|title=Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more|accessdate=26 November 2013|work=Medscape Reference|publisher=WebMD|url=http://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979#showall|archive-date=2 December 2013|archive-url=https://web.archive.org/web/20131202221232/http://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979#showall|url-status=live}}</ref>
<!--Chemical data-->|C=17|H=20|N=4|S=1|molecular_weight=312.439|smiles=CN1CCN(CC1)C/2=N/c4ccccc4Nc3sc(C)cc\23|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}|StdInChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N|melting_point=195|solubility=Practically insoluble in water}}
'''Olanzapine''' adalah golongan antipsikotik atipikal yang digunakan untuk mengatasi [[skizofrenia]] dan [[gangguan bipolar]] . <ref name="AHFS2018">{{Cite web|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live |access-date=24 December 2018}}</ref> Pada pasien skizofrenia, obat ini bisa digunakan untuk jangka pendek dan bisa digunakan terapi pemeliharaan jangka panjang. <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref> Rute pemberian obat melalui oral atau bisa [[penyuntikan intraotot]] . <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref>
Kemunculan efek samping yang umum pada penggunaan obat ini meliputi penambahan berat badan, gangguan pergerakan, pusing, rasa lelah, sembelit, dan mulut kering. <ref name="AHFS2018">{{Cite web|title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live |access-date=24 December 2018}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html "Olanzapine, Olanzapine Pamoate Monograph for Professionals"]. ''Drugs.com''. AHFS. [https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html Archived] from the original on 6 November 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2018</span>.</cite></ref> Efek samping lainnya yang bisa terjadi pada penggunaan obat ini yakni [[Hipotensi ortostatik|hiptensi ostostatik]], [[Alergi|reaksi alergi]], sindrom neuroleptik maligna, [[hiperglikemia]], [[sawan]], [[ginekomastia]], [[disfungsi ereksi]], dan tardive dyskinesia . <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref> Penggunaan obat ini golongan lansia dengan riwayat [[demensia]], meningkatkan risiko kematian. <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref> Untuk penggunaan trismester akhir pada [[kehamilan]] bisa menyebabkan gangguan pergerakan pada bayi selama beberapa waktu pasca dilahirkan. <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref> Walaupun mekanisme kerjan dari obat ini belum sepenuhnya jelas, obat ini bisa memblokir [[Reseptor serotonin|reseptor]] dopamin dan serotonin. <ref name="AHFS2018">{{cite web |title=Olanzapine, Olanzapine Pamoate Monograph for Professionals |url=https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |website=Drugs.com |publisher=AHFS |accessdate=24 December 2018 |language=en |archive-date=6 November 2018 |archive-url=https://web.archive.org/web/20181106213841/https://www.drugs.com/monograph/olanzapine-olanzapine-pamoate.html |url-status=live }}</ref>
== Referensi ==
|
